STOCK TITAN

MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

MYND Life Sciences has received a grant of $45,600 from the Government of Canada to support research on the effects of psilocybin in treating brain diseases. The funding will aid a project titled Phytochemical-analog(s) as a novel method for management of treatment-resistant depression, running from November 2021 to March 2022. The project aims to explore how psilocybin analogs can modulate brain function by targeting specific gene pathways. The company is committed to advancing neuro-pharmaceutical innovations.

Positive
  • Secured $45,600 funding from the Government of Canada.
  • Research project aims to advance treatment options for depression.
  • Collaboration with National Research Council enhances R&D capabilities.
Negative
  • None.

R&D project on psilocybin's benefits in treating diseases of the brain

VANCOUVER, BC, Nov. 30, 2021 /PRNewswire/ - MYND Life Sciences Inc.  ("MYND" or the "Company") (CSE: MYND) (OTC: MYNDF) is pleased and extremely grateful to acknowledge the financial contribution from the Government of Canada towards an important component of its research and development into the positive effects of psilocybin on treating diseases of the brain.

MYND Life Sciences will benefit from advisory services and up to $45,600 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support a prescribed research and development project that will run from November 2021 to March 2022.

"We are very pleased for the support from the Government of Canada, both from the business advisory perspective, as well as the valued funding support," said Dr. Lyle Oberg, MD, CEO, MYND Life Sciences. "We are taking a broad-based, measured approach to harness private capital  investment, invaluable university research infrastructure, and guidance backed with funding from important government research enablers to tackle some of the most serious diseases of the brain and central nervous system."

The project is titled Phytochemical-analog(s) as a novel method for management of treatment resistant depression. The objective of the research and development is to determine how psilocybin analogs target a particular gene pathway to modulate brain function.

"This support through NRC IRAP is well timed and will enable an important piece of our overall approach to creating novel innovations to improve the lives of people suffering from diseases of the Central Nervous System," stated Dr. Wilfred Jefferies, Chief Science Officer, MYND Life Sciences.

ABOUT MYND LIFE SCIENCES INC.

MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines. The Company is advancing pharmaceuticals through rigorous science and clinical trials, while diligently patenting and safeguarding its intellectual property. For more information and to subscribe to MYND's mailing list, please visit https://myndsciences.com/contact/.

CONTACT INFORMATION
Dr. Lyle Oberg, MD, CEO
Email: ir@myndsciences.com 
Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.  

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mynd-life-sciences-announces-funding-for-psilocybin-research-on-neuroinflammation-301433786.html

SOURCE Mynd Life Sciences Inc.

FAQ

What funding has MYND Life Sciences received for its psilocybin research?

MYND Life Sciences received $45,600 from the Government of Canada to support its psilocybin research project.

What is the focus of MYND Life Sciences' research project?

The focus is on developing psilocybin analogs for managing treatment-resistant depression.

When is the MYND Life Sciences research project scheduled to run?

The research project is scheduled to run from November 2021 to March 2022.

How does the funding from Canada benefit MYND Life Sciences?

The funding supports research and development aimed at innovative treatments for brain diseases.

MYND LIFE SCIENCS INC

OTC:MYNDF

MYNDF Rankings

MYNDF Latest News

MYNDF Stock Data

3.23M
9.79M
59.83%
Biotechnology
Healthcare
Link
United States of America
Port Coquitlam